Skip to main content
Therma Bright Inc. logo

Therma Bright Inc. — Investor Relations & Filings

Ticker · THRM ISIN · CA8834262070 LEI · 529900PN7P0GSORO2174 TSXV Manufacturing
Filings indexed 525 across all filing types
Latest filing 2024-04-01 Regulatory Filings
Country CA Canada
Listing TSXV THRM

About Therma Bright Inc.

https://www.thermabright.com/

Therma Bright Inc. is a medical technology company that develops, acquires, and markets proprietary diagnostic and medical device technologies for the consumer and institutional healthcare sectors. The company's portfolio addresses key areas including pain management, circulation, diagnostics, and critical care. Core products and development projects include Venowave, a medical device designed to boost circulation and prevent blood clots; the Digital Cough Test (DCT), an AI-powered application developed with AI4LYF for rapid, non-invasive detection of respiratory diseases; and the PREVA™ clot retriever, developed with Inretio for enhanced thrombectomy procedures in ischemic stroke treatment. Furthermore, Therma Bright is advancing inhaled statin therapy in partnership with InVixa for the treatment of COVID-19 pneumonia and Acute Respiratory Distress Syndrome (ARDS).

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-04-01 English
Interim MD&A - English.pdf
Regulatory Filings
2024-04-01 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-04-01 English
Material change report - English.pdf
Regulatory Filings
2024-03-21 English
News release - English.pdf
Regulatory Filings
2024-03-21 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and includes details about a material change event dated February 6, 2024. It describes a news release about Therma Bright's Venowave device being accepted for review by the Center for Medicare & Medicaid Services and the resumption of trading on the TSX Venture Exchange. The document is a regulatory disclosure of a material change, not a full financial report or earnings release. It is a formal announcement of a significant corporate event, consistent with a material change report under Canadian securities regulations. The document length is 5466 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.